

Man-Fung Yuen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1430281/man-fung-yuen-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

478
papers

24,282
citations

77
h-index

138
g-index

528
ext. papers

28,614
ext. citations

7
avg, IF

6.82
L-index

#	Paper	IF	Citations
478	Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.. <i>The Lancet Global Health</i> , 2022 , 10, e278-e287	13.6	6
477	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , 2022 , 56, e31-e37	3	0
476	RNA interference as a novel treatment strategy for chronic hepatitis B infection.. <i>Clinical and Molecular Hepatology</i> , 2022 ,	6.9	6
475	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction.. <i>Frontiers in Microbiology</i> , 2022 , 13, 813783	5.7	0
474	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma.. <i>Hepatology International</i> , 2022 , 1	8.8	0
473	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.. <i>Digestive Diseases and Sciences</i> , 2022 , 1	4	
472	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 396-415	18.8	11
471	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , 2021 , 73, 2167-2179	11.2	17
470	A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis. <i>Clinical Infectious Diseases</i> , 2021 , 73, e304-e311	11.6	8
469	Patient plgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
468	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , 2021 ,	13.3	9
467	Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure. <i>Hepatology International</i> , 2021 , 1	8.8	1
466	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2021 , 16, 48	8.8	2
465	First week is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. <i>Hepatology International</i> , 2021 , 15, 1376-1388	8.8	1
464	Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1725-1734	50.5	14
463	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2021 ,	19.2	7
462	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2021 , 21, 123	3	3

461	RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies. <i>Viruses</i> , 2021 , 13,	6.2	3
460	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021 , 7, 88	6.9	5
459	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1890-1899	7	4
458	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. <i>Hepatology International</i> , 2021 , 15, 881-891	8.8	0
457	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
456	Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. <i>Viruses</i> , 2021 , 13,	6.2	5
455	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021 , 15, 901-911	8.8	1
454	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2089-2097	14.6	6
453	APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. <i>Hepatology International</i> , 2021 , 15, 833-851	8.8	8
452	Biological Gradient of Chronic Hepatitis B. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 593	24.2	0
451	REPLY. <i>Hepatology</i> , 2021 , 74, 533-534	11.2	
450	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 46-60.e8	6.9	15
449	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 1315-1326	4	5
448	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , 2021 , 70, 775-783	19.2	18
447	Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies. <i>Liver Transplantation</i> , 2021 , 27, 134-139	4.5	1
446	Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. <i>Hepatology</i> , 2021 , 73, 2326-2341	11.2	10
445	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021 , 15, 71-81	8.8	4
444	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021 , 36, 134-145	3.5	1

443	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 408-409	6.9	
442	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021 , 56, 479-488	6.9	6
441	Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021 , 74, 1795-1808	11.2	3
440	Author Reply: Is the HBsAg response to RO7062931 an antisense effect?. <i>Hepatology</i> , 2021 ,	11.2	0
439	Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 723-732	18.8	10
438	Therapeutic vaccine BR11-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. <i>JHEP Reports</i> , 2021 , 3, 100361	10.3	3
437	Novel Therapy for Functional Cure of Chronic Hepatitis B Virus Infection 2021 , 455-473		
436	Detection of the hepatitis B surface antigen in patients with occult hepatitis B using an assay with enhanced sensitivity.. <i>Journal of Clinical Microbiology</i> , 2021 , jcm0220421	9.7	0
435	Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study. <i>Journal of Hepatology</i> , 2020 , 73, S140	13.4	9
434	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020 , 14, 1023-1033	8.8	10
433	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	17
432	Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. <i>Journal of Hepatology</i> , 2020 , 73, 952-964	13.4	41
431	Rebound of HBV DNA after cessation of nucleos(t)ide analogues in chronic hepatitis B patients with undetectable covalently closed. <i>JHEP Reports</i> , 2020 , 2, 100112	10.3	9
430	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , 2020 , 73, 800-806	13.4	19
429	Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , 2020 , 19, 293-301	1	3
428	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020 , 10, 802	4.9	9
427	A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS601-TPS601	2.2	3
426	Hepatocellular carcinoma: recent advances and emerging medical therapies. <i>F1000Research</i> , 2020 , 9,	3.6	21

425	Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 554-561	6.9	1
424	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020 , 14, 665-668	4.8	2
423	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 152-166	18.8	49
422	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31	11.2	47
421	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020 , 72, 818-828	11.2	5
420	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020 , 115, 271-280	0.7	45
419	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 397-406	3.4	8
418	Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <i>Hepatology International</i> , 2020 , 14, 35-46	8.8	14
417	Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , 2020 , 73, 1573-1574	13.4	17
416	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00236	4.2	9
415	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020 , 4, 1624-1636	6	13
414	Modulation of gut microbiota mediates berberine-induced expansion of immuno-suppressive cells to against alcoholic liver disease. <i>Clinical and Translational Medicine</i> , 2020 , 10, e112	5.7	18
413	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00196	4.2	4
412	Nidogen 1-Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. <i>Advanced Science</i> , 2020 , 7, 2002157	13.6	18
411	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1540-1550	6.1	6
410	Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. <i>Journal of Hepatology</i> , 2020 , 73, S20	13.4	16
409	Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos (t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study. <i>Journal of Hepatology</i> , 2020 , 73, S49-S50	13.4	15
408	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 221, 389-399	7	22

407	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 449-456	6.9	28
406	GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial. <i>Journal of Hepatology</i> , 2019 , 70, e47-e48	13.4	21
405	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1924-1933	7	17
404	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019 , 13, 148-156	8.8	8
403	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. <i>Hepatology International</i> , 2019 , 13, 353-390	8.8	218
402	PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg Journal of Hepatology, 2019 , 70, e51-e52	13.4	24
401	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019 , 71, 397-408	13.4	163
400	LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019 , 70, e130	13.4	18
399	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019 , 220, 940-950	7	2
398	FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients. <i>Journal of Hepatology</i> , 2019 , 70, e491	13.4	13
397	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 818-827	3.4	19
396	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , 2019 , 39, 1217-1225	7.9	5
395	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019 , 156, 1392-1403.e7	13.3	73
394	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 545-558	18.8	187
393	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019 , 19, 789	4.8	7
392	Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 351	12.8	8
391	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1473-1480	3.4	7
390	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 3630-3641	4	

389	Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. <i>Current Hepatology Reports</i> , 2019 , 18, 503-511	1	5
388	Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. <i>Hepatology International</i> , 2019 , 13, 695-705	8.8	22
387	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1398-1408	5.6	9
386	New Biomarkers of Chronic Hepatitis B. <i>Gut and Liver</i> , 2019 , 13, 589-595	4.8	23
385	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1817-1823	4	9
384	Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. <i>American Journal of Gastroenterology</i> , 2019 , 114, 929-937	0.7	25
383	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31
382	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019 , 156, 635-646.e9	13.3	86
381	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 109-120	3.8	20
380	Hepatitis B Virus: Asian Perspective 2019 , 99-116		2
379	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1410-1412	6.9	7
378	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 730-737	6.1	42
377	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 101-106	5.5	2
376	A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants. <i>Clinical Therapeutics</i> , 2018 , 40, 719-732.e1	3.5	3
375	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 483-491	5.5	4
374	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. <i>Hepatology</i> , 2018 , 68, 462-472	11.2	39
373	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
372	Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. <i>Journal of Hepatology</i> , 2018 , 69, 121-128	13.4	9

371	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 575-583.e2	6.9	46
370	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 43-54	6.1	105
369	Expansion of Granulocytic, Myeloid-Derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. <i>Frontiers in Immunology</i> , 2018 , 9, 1524	8.4	6
368	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. <i>Liver International</i> , 2018 , 38, 1911-1919	7.9	8
367	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study. <i>Journal of Hepatology</i> , 2018 , 68, S478	13.4	3
366	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18035	51.1	250
365	Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1720-1721	6.1	0
364	RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV. <i>Journal of Hepatology</i> , 2018 , 68, S526	13.4	8
363	Occult Hepatitis B Infection 2018 , 297-313		
362	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018 , 38, 1179-1187	7.9	16
361	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 97-104	3.4	42
360	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 262-279	7.1	99
359	Should red blood cell transfusion be immediately given to a cirrhotic patient with active upper gastrointestinal bleeding?. <i>AME Medical Journal</i> , 2018 , 3, 83-83	1	1
358	Risk Factors for Graft Steatosis after Liver Transplantation using Controlled Attenuation Parameter Measurements. <i>Transplantation</i> , 2018 , 102, S863	1.8	
357	Chronic hepatitis B virus infection. <i>Lancet, The</i> , 2018 , 392, 2313-2324	40	206
356	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018 , 8, 7958	4.9	23
355	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 163	4.2	18
354	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 161-176	18.8	1196

353	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 501-509	6.1	22
352	The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017 , 37, 1287-1294	7.9	4
351	Letter: is body-mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B? AuthorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 483	6.1	
350	Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017 , 1860, 491-501	6	30
349	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 654-661	3.4	44
348	Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. <i>Liver International</i> , 2017 , 37, 1497-1507	7.9	19
347	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017 , 144, 1-7	10.8	28
346	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen. <i>Journal of Hepatology</i> , 2017 , 66, S27	13.4	16
345	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017 , 52, 1064-1074	6.9	9
344	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , 2017 , 66, 1036-1044	11.2	70
343	Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of the Golden window? A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1989-1997	4.7	31
342	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017 , 65, 1451-1461	11.2	60
341	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017 , 37, 995-1001	7.9	91
340	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 1153-1159	11.2	23
339	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	216
338	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e116	4.2	35
337	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , 2017 , 101, 2391-2398	1.8	3
336	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e125	4.2	64

335	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e100	4.2	20
334	Response to Toyoda et al. <i>American Journal of Gastroenterology</i> , 2017 , 112, 970	0.7	
333	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2017 , 49, 202-206	3.3	11
332	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1230-1233	4	14
331	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017 , 66, 275-281	13.4	97
330	Nonalcoholic fatty liver disease in Asia: emerging perspectives. <i>Journal of Gastroenterology</i> , 2017 , 52, 164-174	6.9	59
329	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017 , 8, 47507-47517	3.3	23
328	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7716-7726	5.6	21
327	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7863-7874	5.6	7
326	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016 , 51, 487-95	6.9	20
325	Viral hepatitis: Immune tolerance in HBV infection: danger lurks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 627-628	24.2	4
324	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1788-1795	0.7	51
323	New pharmacological approaches to a functional cure of hepatitis B. <i>Clinical Liver Disease</i> , 2016 , 8, 83-88	2.2	15
322	Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000119	3.9	5
321	Relation of Tricuspid Regurgitation to Liver Stiffness Measured by Transient Elastography in Patients With Left-Sided Cardiac Valve Disease. <i>American Journal of Cardiology</i> , 2016 , 117, 640-646	3	11
320	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 697-707	4.2	10
319	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 383-92	4.1	18
318	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016 , 65, 887-8	19.2	25

317	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016 , 10, 407-14	8.8	16
316	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 183-93	3.7	8
315	Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 290.e1-3	9.5	6
314	IRE1 α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 43792-43804	3.3	13
313	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , 2016 , 10, 332-9	4.8	307
312	Clinical implication of occult hepatitis B infection. <i>Annals of Blood</i> , 2016 , 2, 5-5	0.6	1
311	Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016 , 2016, 8762345	2.3	12
310	New Exploration of Chinese Herbal Medicines in Hepatology. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016 , 2016, 3056438	2.3	
309	Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. <i>International Journal of Molecular Sciences</i> , 2016 , 17, 465	6.3	72
308	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0148493	3.7	17
307	Gastroesophageal Reflux Disease: Cross-Sectional Study Demonstrating Rising Prevalence in a Chinese Population. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, e1-7	3	22
306	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016 , 36, 642-50	7.9	5
305	Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 286-94	3	36
304	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 1638-45	4	8
303	World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 691-703	3	8
302	Differential Reductions in Viral Antigens Expressed from CCCDNAs Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520. <i>Journal of Hepatology</i> , 2016 , 64, S390-S391	13.4	18
301	Interleukin-1 β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016 , 11, 2919-2924	2.6	15
300	Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1071-1079	6.1	19

299	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015 , 64, 667-72	19.2	148
298	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015 , 121, 97-108	10.8	105
297	Management of chronic hepatitis B in patients from special populations. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015 , 5,	5.4	2
296	Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. <i>Journal of Ethnopharmacology</i> , 2015 , 176, 35-48	5	87
295	Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015 , 35, 854-9	7.9	5
294	Hepatitis B in 2014: HBV research moves forward--receptors and reactivation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 70-2	24.2	9
293	Anti-viral therapy in hepatitis B virus reactivation with acute-on-chronic liver failure. <i>Hepatology International</i> , 2015 , 9, 373-7	8.8	10
292	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. <i>Liver Transplantation</i> , 2015 , 21, 1504-10	4.5	18
291	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015 , 6, 34941-52	3.3	38
290	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0139478	3.7	8
289	High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census. <i>Liver International</i> , 2015 , 35, 542-9	7.9	59
288	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. <i>Journal of Hepatology</i> , 2015 , 62, 526-32	13.4	38
287	Measuring and Validating a General Cancer Predisposition Perception Scale: An Adaptation of the Revised-IPQ-Genetic Predisposition Scale. <i>PLoS ONE</i> , 2015 , 10, e0142620	3.7	3
286	Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1764-70	0.7	15
285	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014 , 20, 1173-80	9.5	77
284	Hepatitis Viruses and Hepatocellular Carcinoma 2014 , 181-192		2
283	Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. <i>Molecular Biology Reports</i> , 2014 , 41, 2989-97	2.8	46
282	Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. <i>Molecular Biology Reports</i> , 2014 , 41, 4713-20	2.8	4

281	Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3209-15	9.7	9
280	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1028-34	4	41
279	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. <i>Journal of Infectious Diseases</i> , 2014 , 210, 701-7	7	9
278	New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. <i>PLoS ONE</i> , 2014 , 9, e86449	3.7	28
277	Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. <i>PLoS ONE</i> , 2014 , 9, e99028	3.7	11
276	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. <i>Hepatology International</i> , 2014 , 8, 453-71	8.8	427
275	Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3736-43	2.2	223
274	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 428-34	4	67
273	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014 , 63, 996-1004	19.2	55
272	Entecavir treatment in kidney transplant recipients infected with hepatitis B. <i>Clinical Transplantation</i> , 2014 , 28, 1010-5	3.8	19
271	HLA-DP and Interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 533-9	4	4
270	Artificial neural network accurately predicts hepatitis B surface antigen seroclearance. <i>PLoS ONE</i> , 2014 , 9, e99422	3.7	7
269	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16053-61	5.6	12
268	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013 , 7, 327-34	8.8	2
267	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 470-7	3.4	22
266	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013 , 58, 923-31	11.2	70
265	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013 , 57, 399-408	11.2	157
264	Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1004-10.e1	6.9	98

263	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013 , 59, 709-16	13.4	43
262	Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. <i>American Journal of Gastroenterology</i> , 2013 , 108, 942-8	0.7	94
261	Chinese Medicines as an Adjuvant Therapy for Unresectable Hepatocellular Carcinoma during Transarterial Chemoembolization: A Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013 , 2013, 487919	2.3	14
260	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013 , 57, 622	11.6	1
259	Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. <i>PLoS ONE</i> , 2013 , 8, e72306	3.7	26
258	HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1695-703	11.6	52
257	Factors for hepatitis B vaccination and abnormal liver function in Chinese patients with inflammatory bowel disease: a single center experience. <i>Journal of Digestive Diseases</i> , 2013 , 14, 596-603 ³⁻³	3.3	4
256	Reply: To PMID 22806323. <i>Hepatology</i> , 2013 , 58, 1857	11.2	1
255	Defining normal liver stiffness range in a normal healthy Chinese population without liver disease. <i>PLoS ONE</i> , 2013 , 8, e85067	3.7	29
254	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. <i>PLoS ONE</i> , 2013 , 8, e66920	3.7	31
253	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013 , 2, 34-6	2.1	
252	Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1890-900	5.6	58
251	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8887-94	5.6	33
250	Acute-on-chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012 , 27, 662-9	4	51
249	Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials. <i>Chinese Medicine</i> , 2012 , 7, 5	4.7	15
248	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2012 , 7, 98-105	8.8	24
247	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2012 , 7, 119-26	8.8	9
246	Rare inborn errors associated with chronic hepatitis B virus infection. <i>Hepatology</i> , 2012 , 56, 1661-70	11.2	20

245	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012 , 6, 696-706	8.8	7
244	A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , 2012 , 7, e32622	3.7	53
243	High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. <i>PLoS ONE</i> , 2012 , 7, e43087	3.7	59
242	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012 , 56, 812-9	11.2	68
241	Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1 β activation of nitric oxide production in gastric cancer cells. <i>Cancer</i> , 2012 , 118, 4969-80	6.4	75
240	Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. <i>Antiviral Therapy</i> , 2012 , 17, 1255-62	1.6	15
239	Future prevention and treatment of chronic hepatitis B infection. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 725-34	3	4
238	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011 , 54, 195-200	13.4	24
237	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011 , 55, 522-528	13.4	30
236	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , 2011 , 12, 568-74	21.7	427
235	A comprehensive HBV array for the detection of HBV mutants and genotype. <i>Clinical Biochemistry</i> , 2011 , 44, 1253-60	3.5	5
234	Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. <i>PLoS ONE</i> , 2011 , 6, e28798	3.7	53
233	Up-regulation of microRNAs, miR21 and miR23a in human liver cancer cells treated with <i>Coptidis rhizoma</i> aqueous extract. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 27-32	2.1	35
232	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26 Suppl 1, 138-43	4	130
231	To stop or not to stop: the quest for long-term viral suppression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011 , 26, 420-2	4	2
230	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 738-44	3.4	38
229	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , 2011 , 18, e200-5	3.4	44
228	Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. <i>Liver International</i> , 2011 , 31, 1494-504	7.9	95

227	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , 2011 , 5, 868-875	8.8	13
226	Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. <i>Current Hepatitis Reports</i> , 2011 , 10, 106-111		8
225	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011 , 10, 235-243		21
224	Stability of hepatitis B surface antigen over time: implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011 , 83, 1900-4	19.7	7
223	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. <i>Hepatology</i> , 2011 , 53, 1148-53	11.2	11
222	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011 , 54, 829-36	11.2	106
221	Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. <i>Clinical Infectious Diseases</i> , 2011 , 52, 624-32	11.6	68
220	Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. <i>Gastroenterology</i> , 2011 , 141, 1212-9	13.3	169
219	Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1264-71	11.7	117
218	Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1766-73	0.7	51
217	Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2011 , 106, 492-6	0.7	46
216	The hepatitis B virus-associated estrogen receptor alpha (ERalpha) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2011 , 43, 640-6	2.8	12
215	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2715-25	5.1	139
214	Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Infectious Diseases</i> , 2011 , 203, 646-54	7	76
213	Nucleic acid testing for the detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011 , 11, 847-8; author reply 849	1.8	1
212	A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , 2011 , 6, e23077	3.7	61
211	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , 2011 , 11, 847-848	1.8	1
210	Systemic corticosteroid and reactivation of chronic hepatitis B. <i>Respirology</i> , 2010 , 15, 1017-8	3.6	9

209	Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 882-9	5.9	29
208	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010 , 59, 1389-93	19.2	47
207	Safety evaluation of telbivudine. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 821-9	4.1	22
206	Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1116-22	0.7	44
205	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010 , 8, 717-26	5.5	15
204	Natural history of chronic hepatitis C: genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010 , 53, 444-8	13.4	33
203	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010 , 4, 386-95	8.8	44
202	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010 , 4, 716-22	8.8	26
201	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010 , 51, 767-76	11.2	36
200	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010 , 82, 1843-9	19.7	12
199	Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2009 , 15, 3288-97	5.6	29
198	The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1940-6; quiz 1947	0.7	61
197	Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1779-85	5.9	18
196	Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. <i>Hepatology</i> , 2009 , 49, 72-9	11.2	133
195	Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. <i>Cancer</i> , 2009 , 115, 5441-9	6.4	47
194	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009 , 3, 269-82	8.8	615
193	The saga of entecavir. <i>Hepatology International</i> , 2009 , 3, 421-4	8.8	2
192	Hepatocellular carcinoma in the Asia pacific region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 346-53	4	361

191	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 955-61	4	55
190	Prevention of hepatocellular carcinoma in hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 1352-7	4	54
189	Occult hepatitis B infection: Incidence, detection and clinical implications. <i>ISBT Science Series</i> , 2009 , 4, 347-351	1.1	3
188	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 964-70	9.5	96
187	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , 2009 , 50, 80-8	13.4	411
186	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases, The</i> , 2009 , 9, 256-64	25.5	34
185	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , 2009 , 374, 662	4.0	9
184	Quality of life and psychological impact in patients with noncardiac chest pain. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 13-8	3	18
183	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009 , 14, 679-85	1.6	4
182	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009 , 14, 679-685	1.6	8
181	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. <i>Liver International</i> , 2008 , 28, 1408-16	7.9	68
180	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 1182-92	4	19
179	HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 135, 1192-9	13.3	305
178	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. <i>Vaccine</i> , 2008 , 26, 6587-91	4.1	62
177	Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1. <i>Cancer Letters</i> , 2008 , 260, 62-71	9.9	23
176	LB80380: a promising new drug for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1581-8	5.9	19
175	Factors affecting physicians' practices related to Helicobacter pylori infection: effect of experience and mode of practice. <i>Digestion</i> , 2008 , 78, 77-81	3.6	2
174	Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1663-73	0.7	147

173	Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1421-6	0.7	43
172	Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. <i>Journal of Infectious Diseases</i> , 2008 , 198, 808-12	7	74
171	Chronic hepatitis B--new goals, new treatment. <i>New England Journal of Medicine</i> , 2008 , 359, 2488-91	59.2	92
170	Telbivudine for chronic hepatitis B: the GLOBE trial. <i>Future Virology</i> , 2008 , 3, 317-323	2.4	2
169	What is the best end point for hepatitis B treatment?. <i>Annals of Internal Medicine</i> , 2008 , 148, 560; author reply 560-1	8	1
168	Effects of aspirin on the development of <i>Helicobacter pylori</i> -induced gastric inflammation and heterotopic proliferative glands in Mongolian gerbils. <i>Helicobacter</i> , 2008 , 13, 20-9	4.9	5
167	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. <i>Gut</i> , 2008 , 57, 98-102	19.2	134
166	Natural history of hepatitis-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008 , 14, 1652-6	5.6	175
165	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. <i>Hepatology</i> , 2007 , 46, 1695-703	11.2	103
164	The natural history of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 6-10	3.4	24
163	Revisiting the natural history of chronic hepatitis B: impact of new concepts on clinical management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 973-6	4	27
162	Prediction of treatment outcomes for lamivudine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 964-5	4	3
161	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2007 , 14, 269-75	3.4	30
160	The natural history of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2007 , 14 Suppl 1, 6-10	3.4	24
159	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 377-82	6.1	31
158	Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1063-7	6.1	22
157	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. <i>Journal of Infection</i> , 2007 , 54, 497-503	18.9	10
156	Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 1412-9	27.4	100

155	Hepatitis B virus genotypes: natural history and implications for treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007 , 1, 321-8	4.2	11
154	Symptom resolution does not predict healing of erosive oesophagitis in Chinese. <i>Digestion</i> , 2007 , 75, 128-34	3.6	12
153	Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 3935-41	9.7	25
152	Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 3942-7	9.7	124
151	The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. <i>Annals of Internal Medicine</i> , 2007 , 147, 58-61	8	135
150	Etiologies of chronic liver diseases in Hong Kong. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 659-64	2.2	19
149	Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2007 , 46, 198-205	13.4	34
148	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007 , 12, 1295-303	1.6	75
147	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. <i>Antiviral Therapy</i> , 2007 , 12, 41-46	1.6	28
146	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007 , 12, 1295-1304	1.6	175
145	Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies. <i>Current Hepatitis Reports</i> , 2006 , 5, 23-33		23
144	Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma. <i>Cancer</i> , 2006 , 106, 1243-9	6.4	25
143	Recommendations and potential future options in the treatment of hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2225-31	4	
142	T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1-7	11.6	70
141	Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. <i>Intervirology</i> , 2006 , 49, 96-8	2.5	31
140	Colonoscopy demand and practice in a regional hospital over 9 years in Hong Kong: resource implication for cancer screening. <i>Digestion</i> , 2006 , 73, 84-8	3.6	12
139	Update on clarithromycin resistance in <i>Helicobacter pylori</i> in Hong Kong and its effect on clarithromycin-based triple therapy. <i>Digestion</i> , 2006 , 73, 101-6	3.6	22
138	Eradication of <i>Helicobacter pylori</i> infection reverses E-cadherin promoter hypermethylation. <i>Gut</i> , 2006 , 55, 463-8	19.2	138

137	All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. <i>Gastroenterology</i> , 2006 , 130, 747-58	13.3	38
136	Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. <i>Gastroenterology</i> , 2006 , 130, 703-14	13.3	96
135	Entecavir. <i>Drugs</i> , 2006 , 66, 1623-1624	12.1	
134	Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells. <i>Digestion</i> , 2006 , 73, 75-83	3.6	17
133	Overcoming the problem of chronic hepatitis B. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006 , 3, 197-202		2
132	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006 , 45, 553-9	13.4	73
131	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006 , 45, 646-53	13.4	116
130	Coexistence between colorectal cancer/adenoma and coronary artery disease: results from 1382 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 535-9	6.1	27
129	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 573-83	6.1	60
128	Stability of E-cadherin methylation status in gastric mucosa associated with histology changes. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 831-6	6.1	10
127	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1179-86	6.1	84
126	A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. <i>Hepatology Research</i> , 2006 , 35, 127-34	5.1	13
125	A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 977-83	1.6	14
124	Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. <i>Antiviral Therapy</i> , 2006 , 11, 779-86	1.6	8
123	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. <i>Antiviral Therapy</i> , 2006 , 11, 779-786	1.6	17
122	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. <i>Antiviral Therapy</i> , 2006 , 11, 909-916	1.6	66
121	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006 , 11, 977-984	1.6	29
120	Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. <i>American Journal of Gastroenterology</i> , 2005 , 100, 1099-103	0.7	35

119	Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. <i>Gastroenterology</i> , 2005 , 128, 361-75	13.3	70
118	Telbivudine: an upcoming agent for chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2005 , 3, 489-94	5.5	7
117	A pilot study of participation in faecal occult blood testing and screening colonoscopy after health education in Hong Kong. <i>European Journal of Cancer Prevention</i> , 2005 , 14, 181-4	2	5
116	Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 301-7	6.1	8
115	Hepatitis C virus infection in adult Chinese hemophilia patients negative for the human immunodeficiency virus: treatment results with interferon and ribavirin. <i>International Journal of Hematology</i> , 2005 , 82, 259-61	2.3	3
114	The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 373-9	3.4	61
113	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. <i>Journal of Viral Hepatitis</i> , 2005 , 12, 513-8	3.4	20
112	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 841-9	6.1	24
111	Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 243-9	6.1	71
110	Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22, 483-8	6.1	22
109	Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. <i>American Journal of Transplantation</i> , 2005 , 5, 1893-900	8.7	15
108	Mannose-binding lectin in chronic hepatitis B virus infection. <i>Hepatology</i> , 2005 , 42, 1037-45	11.2	79
107	Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. <i>Cancer</i> , 2005 , 104, 740-6	6.4	36
106	Comparison of the COBAS TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum. <i>Journal of Medical Virology</i> , 2005 , 77, 486-90	19.7	10
105	Serological markers of liver cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2005 , 19, 91-9	2.5	95
104	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. <i>Hepatology Research</i> , 2005 , 33, 216-24	5.1	51
103	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. <i>Gut</i> , 2005 , 54, 1610-4	19.2	276
102	Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. <i>Carcinogenesis</i> , 2005 , 26, 541-6	4.6	86

101	Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 1594-9	9.7	5
100	The role of cholecystectomy in reducing recurrent gallstone pancreatitis. <i>Endoscopy</i> , 2004 , 36, 206-11	3.4	11
99	Specific considerations in the design of hepatitis B virus clinical studies in the far East. <i>Methods in Molecular Medicine</i> , 2004 , 96, 457-64		2
98	Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. <i>Cancer Research</i> , 2004 , 64, 5787-94	10.1	52
97	Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necroinflammation and fibrosis. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3920-4	9.7	18
96	Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3438-40	9.7	33
95	Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3513-7	9.7	10
94	Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3932-6	9.7	12
93	Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 5036-40	9.7	31
92	Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. <i>Journal of Virology</i> , 2004 , 78, 13591-9	6.6	119
91	Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. <i>American Journal of Gastroenterology</i> , 2004 , 99, 2032-7	0.7	47
90	HBSAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 4882-4	9.7	19
89	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , 2004 , 25, 1593-8	4.6	85
88	Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, 31-7	4	29
87	Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: six-hour versus overnight observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004 , 19, 1163-8	4	12
86	Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 1153-8	6.1	46
85	Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20, 675-81	6.1	13
84	PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. <i>Oncogene</i> , 2004 , 23, 4182-6	9.2	94

83	Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 401-6	6.1	6
82	HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. <i>Hepatology</i> , 2004 , 39, 1694-701	11.2	198
81	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. <i>Hepatology</i> , 2004 , 40, 727-37	11.2	111
80	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2004 , 40, 719-26	11.2	86
79	Hepatitis B virus genotype A and D and clinical outcomes of liver transplantation for HBV-related disease. <i>Liver Transplantation</i> , 2004 , 10, 58-64	4.5	46
78	Adefovir dipivoxil in chronic hepatitis B infection. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2361-7	4	19
77	Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. <i>Gastroenterology</i> , 2004 , 126, 136-47	13.3	50
76	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 941-5	6.9	78
75	Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. <i>Journal of Hepatology</i> , 2004 , 40, 1008-17	13.4	25
74	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , 2004 , 41, 119-25	13.4	60
73	New Antiviral Treatment for Chronic Hepatitis B 2004 , 47-56		
72	Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. <i>Clinical Infectious Diseases</i> , 2003 , 37, 593-7	11.6	34
71	Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. <i>Gut</i> , 2003 , 52, 502-6	19.2	222
70	A prospective comparison of performance of biopsy forceps used in single passage with multiple bites during upper endoscopy. <i>Endoscopy</i> , 2003 , 35, 338-42	3.4	9
69	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1181-5	0.7	36
68	Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. <i>Intervirology</i> , 2003 , 46, 373-6	2.5	24
67	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. <i>Hepatology</i> , 2003 , 37, 562-7	11.2	126
66	Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. <i>Cancer</i> , 2003 , 97, 2420-4	6.4	47

65	A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. <i>Cancer</i> , 2003 , 97, 2776-82	6.4	11
64	Evaluation of two stool antigen tests for the detection of <i>Helicobacter pylori</i> infection in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 26-31	4	10
63	Cholangiocarcinoma in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 337-41	4	11
62	Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003 , 18, 534-9	4	31
61	Evaluation of a rapid stool antigen test for the diagnosis of <i>Helicobacter pylori</i> infection in Chinese patients. <i>Chinese Journal of Digestive Diseases</i> , 2003 , 4, 132-135		3
60	Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 289-96	6.1	60
59	Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17, 553-60	6.1	97
58	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1181-1185	0.7	3
57	Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis?. <i>Gastrointestinal Endoscopy</i> , 2003 , 58, 500-4	5.2	59
56	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003 , 39, 850-5	13.4	49
55	Viral hepatitis B. <i>Lancet, The</i> , 2003 , 362, 2089-94	40	638
54	Viral hepatitis C. <i>Lancet, The</i> , 2003 , 362, 2095-100	40	683
53	Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. <i>Annals of Oncology</i> , 2003 , 14, 1463-7	10.3	41
52	Prognostic factors in severe exacerbation of chronic hepatitis B. <i>Clinical Infectious Diseases</i> , 2003 , 36, 979-84	11.6	42
51	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. <i>Gut</i> , 2003 , 52, 416-9	19.2	97
50	Current and future antiviral agents for chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 481-5	5.1	7
49	Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. <i>Journal of Infectious Diseases</i> , 2003 , 187, 1071-4	7	56
48	Effects of primary metronidazole and clarithromycin resistance to <i>Helicobacter pylori</i> on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. <i>Clinical Infectious Diseases</i> , 2003 , 37, 882-9	11.6	28

47	Clinical experience and follow-up with lamivudine in the Asian population 2003 , 383-390		
46	Reversal of protein-losing enteropathy by liver transplantation. <i>Journal of Clinical Gastroenterology</i> , 2003 , 36, 86-7	3	8
45	Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. <i>Cancer Research</i> , 2003 , 63, 7724-32	10.1	114
44	Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. <i>Antiviral Therapy</i> , 2003 , 8, 531-4	1.6	21
43	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. <i>Antiviral Therapy</i> , 2003 , 8, 531-534	1.6	49
42	Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. <i>Journal of Medical Virology</i> , 2002 , 67, 334-8	19.7	16
41	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002 , 94, 1747-52	6.4	188
40	An evaluation of a rapid urine test for the diagnosis of <i>Helicobacter pylori</i> infection in the Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 813-7	6.1	13
39	Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 929-36	6.1	54
38	Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 2037-42	6.1	74
37	One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of <i>Helicobacter pylori</i> infection in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 2067-72	6.1	11
36	Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 432-7	4	1
35	A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. <i>Hepatology</i> , 2002 , 36, 687-91	11.2	130
34	Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. <i>New England Journal of Medicine</i> , 2002 , 346, 2033-8	59.2	480
33	A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. <i>Gut</i> , 2002 , 51, 245-7	19.2	31
32	Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn's disease: a cautionary tale. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1679-81	1.9	5
31	Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. <i>Journal of Infectious Diseases</i> , 2002 , 186, 1335-8	7	73
30	Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 272-5	3	2

29	Mirtazapine-induced hepatotoxicity. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 270-1	3	40
28	Role of cholecystectomy in preventing recurrent cholangitis. <i>Gastrointestinal Endoscopy</i> , 2002 , 56, 55-60	5.2	8
27	Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2002 , 37, 233-8	2.4	43
26	Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. <i>Gut</i> , 2002 , 51, 502-6	19.2	87
25	Acute hepatitis as a presentation of acute appendicitis in an immunocompromised patient. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, 203-4	3	
24	One-week ranitidine bismuth citrate-based triple therapy for the eradication of <i>Helicobacter pylori</i> in Hong Kong with high prevalence of metronidazole resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 403-9	6.1	22
23	Three-day lansoprazole quadruple therapy for <i>Helicobacter pylori</i> -positive duodenal ulcers: a randomized controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 843-9	6.1	10
22	Acute cholangitis—predictive factors for emergency ERCP. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1633-7	6.1	45
21	Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001 , 15, 1959-65	6.1	25
20	Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. <i>Journal of Viral Hepatitis</i> , 2001 , 8, 459-64	3.4	19
19	Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. <i>Cancer</i> , 2001 , 91, 106-12	6.4	112
18	Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. <i>Cancer</i> , 2001 , 92, 2136-41	6.4	12
17	Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. <i>Hepatology</i> , 2001 , 34, 139-45	11.2	177
16	Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. <i>Hepatology</i> , 2001 , 34, 785-91	11.2	303
15	The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus. <i>American Journal of Gastroenterology</i> , 2001 , 96, 838-41	0.7	11
14	Low molecular weight heparin-induced liver toxicity. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 691-4	2.9	25
13	Tension pneumothorax complicating ERCP in a patient with a Billroth II gastrectomy. <i>Gastrointestinal Endoscopy</i> , 2001 , 54, 254-6	5.2	7
12	Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Clinical Immunology</i> , 2001 , 101, 264-9	9	17

11	Treatment of chronic hepatitis B. <i>Lancet Infectious Diseases, The</i> , 2001 , 1, 232-41	25.5	76
10	Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. <i>Annals of Surgery</i> , 2001 , 233, 276-81	7.8	110
9	Profound suppression of hepatitis B virus replication with lamivudine. <i>Journal of Medical Virology</i> , 2000 , 61, 367-73	19.7	39
8	Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. <i>Hepatology</i> , 2000 , 31, 201-6	11.2	198
7	Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. <i>Hepatology</i> , 2000 , 31, 330-5	11.2	366
6	Evaluation of a new referral system for the management of dyspepsia in Hong Kong: Role of open-access upper endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1251-1256	4	2
5	Natural history of chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15 Suppl, E20-4	4	51
4	Evaluation of a new referral system for the management of dyspepsia in Hong Kong: Role of open-access upper endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15, 1251-1256	4	3
3	Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. <i>Hepatology</i> , 1999 , 29, 924-7	11.2	57
2	Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. <i>Hepatology</i> , 1999 , 29, 1248-51	11.2	69
1	Nucleic acid-based cross-linking assay for detection and quantification of hepatitis B virus DNA. <i>Journal of Clinical Microbiology</i> , 1999 , 37, 161-4	9.7	27